Ind-Swift (INDSWFTLAB) | Stock Overview & Key Data
Ind-Swift Performance Comparison
Stock Range
Today's Range
Low: ₹95.00
High: ₹99.90
on October 3, 2025
52 Week Range
Low: ₹68.72
High: ₹134.40
on May 9, 2025
on October 21, 2024
All-Time High: ₹296.50 on December 20, 2004
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR8.2B
EPS
35.21
P/E Ratio (TTM)
2.77
Forward P/E
N/A
P/B Ratio
0.56
PEG Ratio
N/A
Div. Yield
N/A
ROE
21.35%
Beta
0.438
Debt to Equity
3.48
Financial Highlights
Profitability
Gross Margin
41.64%
Operating Margin
-2.01%
Profit Margin
40.55%
Returns and Earnings
Return on Assets (TTM)
17.41%
Return on Equity (TTM)
21.35%
EBITDA
INR317.3M
Net Income (TTM)
INR2.3B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR93.61
Quarterly Revenue Growth (YoY)
360.50%
Quarterly Earnings Growth (YoY)
837.90%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ind-Swift INDSWFTLAB | 8.21B Small-cap | -2.69% | -5.20% | -15.14% | 6.00% | -11.60% | -23.43% | 71.35% | 64.81% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Suven Life Sciences SUVEN | 48.20B Small-cap | -0.17% | -3.10% | -15.83% | 58.82% | 63.15% | 46.77% | 186.97% | 307.88% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Aarti Drugs AARTIDRUGS | 44.55B Small-cap | 4.61% | 0.24% | 1.59% | 41.06% | 7.93% | -4.79% | -0.89% | -50.06% |
Ownership & Short Interest
Insider Ownership
69.57%
Institutional Ownership
5.46%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
35K
Average 90-Day Volume
40K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is INDSWFTLAB's 52-week high and low?
- In the last 52 weeks, Ind-Swift reached a high of ₹134.40 (on October 21, 2024) and a low of ₹68.72 (on May 9, 2025).
- What is the market cap and P/E ratio for INDSWFTLAB?
- Curious about Ind-Swift's size and valuation? Its market capitalization stands at 8.21B. When it comes to valuation, the P/E ratio (trailing twelve months) is 2.77, and the forward P/E (looking ahead) is N/A.
- Does INDSWFTLAB pay dividends? If so, what's the yield?
- As for dividends, Ind-Swift isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ind-Swift's main competitors or similar companies to consider before investing?
When looking at Ind-Swift, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Suven Life Sciences
SUVEN48.20B Healthcare Drug Manufacturers - Specialty & Generic 46.77% 186.97% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Aarti Drugs
AARTIDRUGS44.55B Healthcare Drug Manufacturers - Specialty & Generic -4.79% -0.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ind-Swift Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Ind-Swift's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 21.35%, the Debt to Equity ratio from the most recent quarter is 3.48, and its Gross Profit Margin stands at 41.64%.
- What is the recent revenue and earnings growth for INDSWFTLAB?
- Looking at Ind-Swift's growth, its revenue over the trailing twelve months (TTM) was INR6B. Compared to the same quarter last year (YoY), quarterly revenue grew by 360.50%, and quarterly earnings saw a YoY growth of 837.90%.
- How much of INDSWFTLAB stock is held by insiders and institutions?
- Wondering who owns Ind-Swift stock? Company insiders (like executives and directors) hold about 69.57% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 5.46%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.